ArticleInfection and immunity2009
An engineered human antibody fab fragment specific for Pseudomonas aeruginosa PcrV antigen has potent antibacterial activity.
Article in Infection and immunity, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 121 citations in OpenAlex.
- Article
- Fc-free single-chain antibody mRNA therapy for airway infection of multidrug-resistant Pseudomonas aeruginosa.Nature communications · 2026Article
- Phage receptor binding protein and Fc fragment fusion enhances phagocytosis of Y. enterocolitica.AMB Express · 2025Article
- Article
- Monitoring In Vivo Performances of Protein-Drug Conjugates Using Site-Selective Dual Radiolabeling and Ex Vivo Digital Imaging.Journal of medicinal chemistry · 2022Article
- Virulence Factors ofFrontiers in cellular and infection microbiology · 2022Review
- Pseudomonas aeruginosa Antivirulence Strategies: Targeting the Type III Secretion System.Advances in experimental medicine and biology · 2022Article
- Potential Therapeutic Targets for Combination Antibody Therapy againstAntibiotics (Basel, Switzerland) · 2021Review
- Production of an Antibody Fragment (scFv) Targeting PcrV Protein of Pseudomonas aeruginosa in Fed-Batch Cultivation ModeIranian biomedical journal · 2021Article
- Characterization of a novel mCH3 conjugated anti-PcrV scFv molecule.Scientific reports · 2021Article
- A Structure-Function-Inhibition Analysis of theJournal of bacteriology · 2020Article
- The RH5-CyRPA-Ripr Complex as a Malaria Vaccine Target.Trends in parasitology · 2020Review
- Targeting CD300f to enhance hematopoietic stem cell transplantation in acute myeloid leukemia.Blood advances · 2020Article
- Monoclonal Antibodies as an Antibacterial Approach Against Bacterial Pathogens.Antibiotics (Basel, Switzerland) · 2020Review
- Epidemiological survey of serum titers from adults against various Gram-negative bacterial V-antigens.PloS one · 2020Article
- Immunoglobulin for Treating Bacterial Infections: One More Mechanism of Action.Antibodies (Basel, Switzerland) · 2019Review
- Epidemiology and Treatment of Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Infections.Clinical microbiology reviews · 2019Review
- Tanshinones: First-in-Class Inhibitors of the Biogenesis of the Type 3 Secretion System Needle ofACS central science · 2019Article
- Thinking Outside the Bug: Molecular Targets and Strategies to Overcome Antibiotic Resistance.International journal of molecular sciences · 2019Review
- Drug Prevention and Control of Ventilator-Associated Pneumonia.Frontiers in pharmacology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pseudomonas aeruginosa is an opportunistic pathogen that can cause acute lung injury and mortality through the delivery of exotoxins by the type III secretion system (TTSS). PcrV is an important structural protein of the TTSS. An engineered human antibody Fab fragment that binds to the P. aeruginosa PcrV protein with high affinity has been identified and has potent in vitro neutralization activity against the TTSS. The instillation of a single dose of Fab into the lungs of mice provided protection against lethal pulmonary challenge of P. aeruginosa and led to a substantial reduction of viable bacterial counts in the lungs. These results demonstrate that blocking of the TTSS by a Fab lacking antibody Fc-mediated effector functions can be sufficient for the effective clearance of pulmonary P. aeruginosa infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.